In phase II studies Apatorsen improved outcomes in bladder, prostate cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

OncoGenex Pharmaceuticals Inc. said apatorsen results from two randomized phase II clinical trials were presented at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
FDA approved Imfinzi (durvalumab)​ in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. 
At the recommended regimen, 73% of patients receiving a pasritamig and JNJ-9401 combination, two bispecific antibodies designed to work together to drive the body’s immune response against advanced prostate cancer, achieved reductions of at least 50% in prostate-specific antigen, according to the results of a first-in-human phase I study. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login